Abstract
The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-β, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the immunoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial least-squares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P=0.0305; survival to 5-years, 80 vs 0%, P=0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.
Similar content being viewed by others
Accession codes
Accessions
GenBank/EMBL/DDBJ
References
Azzarelli BN, Miravalle LN and Vidal RN . (2003). J. Neuropathol. Exp. Neurol., 62, 544.
Blumcke I, Becker AJ, Normann S, Hans V, Riederer BM, Krajewski S, Wiestler OD and Reifenberger G . (2001). J. Neuropathol. Exp. Neurol., 60, 984–993.
Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA and Louis DN . (1998). J. Natl. Cancer Inst., 90, 1473–1479.
Durand JF, Roman S and Vivien M (eds) (2001). Guide d'utilisation de la Regression Partial Least Squares Lineaire sous Splus. Universite Montpellier II: Montpellier.
Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK and Zhang W . (1999). Cancer Res., 59, 4228–4232.
Grifa A, Totaro A, Rommens JM, Carella M, Roetto A, Borgato L, Zelante L and Gasparini P . (1998). Biochem. Biophys. Res. Commun., 250, 240–245.
Gunthert AR, Grundker C, Hollmann K and Emons G . (2002). Biochem. Biophys. Res. Commun., 294, 11–15.
Gutmann DH, Hedrick NM, Li J, Nagarajan R, Perry A and Watson MA . (2002). Cancer Res., 62, 2085–2091.
Hall A . (1998). Science, 279, 509–514.
Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P and Ohgaki H . (2000). Cancer Res., 60, 6868–6874.
Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG and Louis DN . (2001). Clin. Cancer Res., 7, 839–845.
Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal MM and Cavenee WK . (2000). Diffuse astrocytoma Pathology and Genetics of Tumours of the Nervous System, Kleihues P and Cavenee WK (eds). IARC Press: Lyon, pp. 22–26.
Li T, Dai W and Lu L . (2002). J. Biol. Chem., 277, 32668–32676.
Ligon KL, Alberta JA, Louis DN, Stiles CD and Rowitch DH . (2003). J. Neuropathol. Exp. Neurol., 62, 544.
Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH and Black PM . (2001). Proc. Natl. Acad. Sci. USA, 98, 10851–10856.
Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B and Hoang-Xuan K . (2001). Lancet, 358, 298–300.
Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB and Benos DJ . (2001). Physiol. Genomics, 5, 21–33.
Miettinen HE, Paunu N, Rantala I, Kalimo H, Paljarvi L, Helin H and Haapasalo H . (2001). J. Neurooncol., 55, 29–37.
Mukasa A, Ueki K, Matsumoto S, Tsutsumi S, Nishikawa R, Fujimaki T, Asai A, Kirino T and Aburatani H . (2002). Oncogene, 21, 3961–3968.
Nguyen DV and Rocke DM . (2002). Bioinformatics, 18, 39–50.
Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB and Aldape K . (2001). Am. J. Pathol., 158, 1253–1262.
Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR and Louis DN . (2003). Cancer Res., 63, 1602–1607.
Obata S, Sago H, Mori N, Rochelle JM, Seldin MF, Davidson M, St John T, Taketani S and Suzuki ST . (1995). J. Cell. Sci., 108 (Part 12), 3765–3773.
Ohnishi A, Sawa H, Tsuda M, Sawamura Y, Itoh T, Iwasaki Y and Nagashima K . (2003). J. Neuropathol. Exp. Neurol., 62, 1052–1059.
Perry JR . (2001). Curr. Opin. Neurol., 14, 705–710.
Peters HC, Kammer G, Volz A, Kaupmann K, Ziegler A, Bettler B, Epplen JT, Sander T and Riess O . (1998). Neurogenetics, 2, 47–54.
Reifenberger G, Kros JM, Burger PC, Louis DN and Collins VP . (2000). Oligodendroglioma Pathology and Genetics of Tumours of the Nervous System, Kleihues P and Cavenee WK (eds). IARC Press: Lyon, pp. 56–61.
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W and Collins VP . (1994). Am. J. Pathol., 145, 1175–1190.
Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J and Hanash SM . (2001). Cancer Res., 61, 6885–6891.
Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP and Kononen J . (2000). Cancer Res., 60, 6617–6622.
Sano K, Tanihara H, Heimark RL, Obata S, Davidson M, St John T, Taketani S and Suzuki S . (1993). EMBO J., 12, 2249–2256.
Schafer JL (ed) (1997). Analysis of Incomplete Multivariate Date. Chapman & Hall: London.
Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW and Jenkins RB . (2000). J. Clin. Oncol., 18, 636–645.
Tanwar MK, Gilbert MR and Holland EC . (2002). Cancer Res., 62, 4364–4368.
Vogt PK . (2001). Oncogene, 20, 2365–2377.
Wagner EF . (2001). Oncogene, 20, 2334–2335.
Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P and Ohgaki H . (1996). Brain Pathol., 6, 217–224.
Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P and Ohgaki H . (2001). Acta Neuropathol., 103, 267–275.
Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD and Rich KM . (2001). Cancer Res., 61, 1825–1829.
Zerbini LF, Wang Y, Cho JY and Libermann TA . (2003). Cancer Res., 63, 2206–2215.
Acknowledgements
This study was supported by a grant of the Foundation for Promotion of Cancer Research, Japan. FLH is a fellow of the Leopoldina foundation and supported by grants of the Bonizzi-Theler- and Stammbach foundation. We are grateful to Mrs N Lyandrat for the technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, H., Okamoto, Y., Yokoo, H. et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 23, 6012–6022 (2004). https://doi.org/10.1038/sj.onc.1207781
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207781
- Springer Nature Limited
Keywords
This article is cited by
-
The long non-coding RNA LOC441204 enhances cell growth in human glioma
Scientific Reports (2017)
-
Gene expression in oligodendroglial tumors
Cellular Oncology (2011)
-
Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment
Current Oncology Reports (2011)
-
Function and regulation of Rnd proteins
Nature Reviews Molecular Cell Biology (2006)
-
Rnd2
AfCS-Nature Molecule Pages (2005)